Analyst Recommendation Overview
TD Cowen analyst Marc Frahm highlighted Agios Pharmaceuticals as the firm’s top pick in the biotech sector, emphasizing the company’s robust thalassemia franchise and an expanding pipeline.
Clinical Data Highlights
- At the European Hematology Association 2026 conference, Agios presented new analyses from the Phase 3 RISE‑UP trial in sickle cell disease, showing a 0.77 g/dL increase in hemoglobin versus 0.03 g/dL for placebo. Transfusion data indicated a 41% relative reduction in the proportion of patients requiring transfusions and a 56% reduction in red‑blood‑cell units transfused per patient, surpassing historical outcomes with hydroxyurea.
- The confirmatory Phase 3 REIGNITE trial will enroll approximately 159 patients, with a primary endpoint of transfusion‑free status from weeks 4 to 52. The study is powered at roughly 98% to detect the primary endpoint.
- In non‑transfusion‑dependent thalassemia, Phase 3 ENERGIZE open‑label extension data demonstrated a sustained hemoglobin benefit, with the mean duration of response more than doubling to about 43.6 weeks. Approximately 60% of patients continuing mitapivat in the extension achieved ≥1 g/dL increases in hemoglobin.
Commercial Progress
- The Aqvesme (mitapivat) launch is tracking ahead of expectations, with about 242 prescriptions recorded by the end of the first quarter. This translates to an implied $82 million annualized demand, exceeding the $63 million FY 2026 consensus.
Early‑Stage Pipeline
- Interim Phase 1 data for AG‑236, an siRNA targeting TMPRSS6 in polycythemia vera, showed dose‑dependent hepcidin induction and pharmacodynamic activity lasting beyond ~57 days, supporting the potential for extended dosing intervals of up to every 24 weeks.
Significance
The presented data reinforce confidence in Agios’s lead asset mitapivat across multiple hematologic indications and suggest that the company can sustain strong early launch performance while advancing its pipeline.